New Drug Combination Shows Promise Against Rare Liver Cancer

Immunotherapy, a treatment that harnesses the body’s own immune system to fight cancer, has historically shown limited success against fibrolamellar carcinoma, a rare and often fatal liver cancer. However, a new study from Cornell University, published February 17, 2026, in the journal Gastroenterology, suggests that combining an existing FDA-approved drug with immunotherapy may overcome this resistance, offering a potential new treatment avenue for patients.

Understanding Fibrolamellar Carcinoma

Fibrolamellar carcinoma primarily affects children and young adults, accounting for up to 2% of all liver cancers. It often metastasizes before detection, leading to a poor prognosis and limited treatment options. The cancer is characterized by thick fibrous bands running through the tumors, the significance of which researchers are still investigating ¹.

How the Combination Therapy Works

The Cornell study identified a key mechanism hindering immunotherapy’s effectiveness in fibrolamellar carcinoma: T-cell exclusion. Tumors rewire their microenvironment to prevent the body’s immune T cells from reaching and attacking the cancer cells. Researchers discovered that AMD3100, a drug already approved by the FDA for other conditions, can prevent this T-cell sequestration, allowing the immune cells to infiltrate the tumor.

When tested on patient tumor slices, AMD3100 effectively mobilized T cells into the core of the tumor. Combining AMD3100 with immune checkpoint inhibition – a common immunotherapy technique – further enhanced T-cell activation and significantly increased the death of tumor cells ².

The Role of CXCR4 Signaling

The study pinpointed CXCR4 chemokine signaling as a crucial driver of this immune exclusion. Therapeutically targeting CXCR4, in conjunction with PD-1 blockade (a type of immune checkpoint inhibition), represents a promising new combination immunotherapy approach ².

Clinical Trials on the Horizon

Researchers, led by Praveen Sethupathy, professor of physiological genomics at Cornell University, are actively seeking liver cancer clinicians to initiate clinical trials for this new treatment combination ³. The fact that AMD3100 is already FDA-approved is expected to expedite the clinical trial process and reduce associated risks.

“Our results provide among the first indications of why a type of immunotherapy called immune checkpoint inhibition hasn’t worked well in these patients, and even if this particular drug isn’t the conclude-all-be-all, it teaches us that this T-cell exclusion phenomenon is an vital one to tackle in fibrolamellar carcinoma,” said Sethupathy ³.

Looking Ahead

While further research and clinical trials are necessary, this study offers a significant step forward in the fight against fibrolamellar carcinoma. The identification of T-cell exclusion as a key barrier to immunotherapy, and the potential of AMD3100 to overcome this barrier, provide a new hope for patients with this challenging cancer.

This research builds on growing understanding of why some cancers resist immunotherapy, highlighting the importance of the tumor microenvironment and immune cell interactions in treatment success ⁴.